

## NEWS RELEASE

### **RYTVEL Biotech is invited to the Hello Tomorrow Challenge Global Summit**

*Rytvela – new treatment for preterm birth*

**Montreal, Canada, September 27, 2016** – **RYTVEL** Biotech is pleased to announce that Hello Tomorrow Challenge has identified the company as one of the most promising Start up around the world. **RYTVEL** is invited to present its **Rytvela** project at the **Hello Tomorrow Challenge Global Summit** that will be held in Paris on October 12 to 14, 2016. **Rytvela** is a new efficient first in class treatment of the cause and ensuing serious consequences of preterm birth.

Three pre-clinical blinded in-vivo studies performed separately and independently have confirmed that **Rytvela** reduces utero-placental inflammation, significantly reduces or suppresses preterm birth (PTB), newborn death and prevents major organ disruption including of brain, yielding normal growth trajectory.

“We are excited to be invited to attend such a prestigious global Summit,” said Jean-Paul Castaigne, MD, MBA, founder and CEO of Rytvel Biotech. “Preterm birth (PTB) is the first cause of mortality and morbidity of newborn (more than one million deaths per year Worldwide) and there are no really effective treatment and none of the one utilized today addresses the utero-placental inflammation, the real cause of PTB and of the insult to the fetus”.

- **Rytvela** is a selective antagonist of the IL-1 receptor with strong anti-inflammatory property
- The data of the independent studies have shown that **Rytvela**:
  - Suppresses utero-placental inflammation
  - Normalizes the term of birth in 90% of the cases
  - Significantly reduces the risks of death at birth
  - Normalizes the organ structure and function (brain, lung and ileum / colon)
  - Is active as a preventive and curative treatment

#### **About RYTVEL Biotech and Rytvela**

**RYTVEL Biotech** will be the first company exploring a new paradigm therapy to develop **Rytvela**, an effective drug to end preterm birth to the benefit of women and newborns. **Rytvela** (a linear 7 amino acid peptide) is the first small drug candidate selective to the major pro-inflammatory interleukin-1 receptor. Pre-clinical studies have been corroborated by three independent academic laboratories (U of Montreal, U of Alberta in Canada, and U of Adelaide, Australia). These blinded studies performed separately and independently demonstrate that **Rytvela** suppresses utero-placental inflammation, significantly reduces/suppresses preterm birth (PTB), newborn death and prevents major organ disruption including of brain, yielding normal growth trajectory. **Rytvela** was invented by Dr Sylvain Chemtob and his team at the CHU Sainte-Justine Research Center in Montreal, Canada.

<https://rytvel.com/>

#### **About the CHU Sainte-Justine Research Center**

CHU Sainte-Justine Research Center is a leading mother-child research institution affiliated with Université de Montréal. It brings together more than 200 research investigators, including over 90 clinician-scientists, as well as 385 graduate and postgraduate students focused on finding innovative prevention means, faster and less invasive treatments, as well as personalized approaches to medicine.

The Center is part of CHU Sainte-Justine, which is the largest mother-child center in Canada and second pediatric center in North America.

### **About PTB (Preterm birth)**

PTB is defined as birth occurring before 37 weeks of gestation (World Health Organization 2012).

It occurs in ~10 % of births (~ 550,000 in North America).

The major cause is utero-placental inflammation (~70%) presumed secondary to infection (clinical and sub clinical) other are dominated by idiopathic and multiple fetuses.

The consequences are newborn death (more than 1 million per year worldwide), severe life-long health handicaps specially brain, lung and ileus/colon.

The current treatments, the tocolytic agents have no or very little efficacy and none of them addresses the utero-placental inflammation.

The costs in the USA were reported by the US Institute of Medicine in 2007 to be \$26 billion/year.

Normal delivery cost \$ 4,500, preterm birth \$ 50,000, and after the neonatal period life time medical care reach \$500,000 per premature handicapped child PTB.

### **About Hello Tomorrow Challenge and the 2016 Global Summit**

Hello Tomorrow is a non-profit organization that aims to bridge the gap between science entrepreneurs, investors, and corporations in all major scientific and technological fields. (*Aeronautics, Air Quality, Beauty and Wellbeing, Data & AI, Energy, Food & Agriculture, Healthcare, Industry 4.0, Transportation & Mobility, Water & Waste*). Today, it is a global, interdisciplinary community of 15,000 innovators, with a presence across 45 countries. The Hello Tomorrow Challenge, a global startup competition, has attracted nearly 5,000 startups across 112 countries since its inception in 2014. To date, €65 million has been raised by Hello Tomorrow's finalists. The [Hello Tomorrow Global Summit](#) is an intimate, invite-only forum that will gather 2,000 science visionaries and entrepreneurs from around the world at the CENTQUATRE in Paris, France on October 12–14, 2016.

- 30 -

### **Media Contacts:**

Daniel Granger, L.L.L., MBA, APR, FSCRIP, IAS

T. +1 514 840-7990

M. + 1 514 232-1556

[daniel.granger@acjcommunication.com](mailto:daniel.granger@acjcommunication.com)

Charlotte Blanche

T. + 1 514 840-1235 ext 7772

M. + 1 514 914-0593

[c.blanche@acjcommunication.com](mailto:c.blanche@acjcommunication.com)

### **Scientific, Financing and BD Contacts:**

Jean Paul Castaigne MD, MBA

CEO RYTVEL Biotech

[jpcastaigne@jpcbitech.com](mailto:jpcastaigne@jpcbitech.com)

+1 514-518-5500

Sylvain Chemtob MD, PhD

CSO RYTVEL Biotech

[sylvain.chemtob@gmail.com](mailto:sylvain.chemtob@gmail.com)

+1 514-585-4604